Adenocarcinoma of the GEJ: Gastric or oesophageal cancer?

Recent Results in Cancer Research

Volumn 196, Issue , 2012, Pages 107-113

  Ruschoff J ^a  

^a Institut fur Pathologie Nordhessen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; PRECANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; STOMACH ADENOCARCINOMA;

EID: 84870027954     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-31629-6_7     Document Type: Article

References (20)

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697
2. Baretton GB, Aust DE (2012) Barrett-ösophagus. Aktueller Stand Pathologe 33: 5-16
3. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system. IARC, Lyon
4. Brown IS, Whiteman DC, Lauwers GY (2010) Foveolar type dysplasia in Barrett esophagus. Mod Pathol 23: 834-843
5. Chandrasoma P, Wijetunge S, De Meester S, Ma Y, Hagen J, Zamis L, DeMeester T (2012) Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am J Surg Pathol 36: 1-7
6. Demicco EG, Farris AB 3rd, Baba Y, Agbor-Etang B, Bergethon K, Mandal R, Daives D, Fukuoka J, Shimizu M, Dias-Santagata D, Ogino S, Iafrate AJ, Gaissert HA, Mino-Kenudson M (2011) The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinaltype vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 24 (9): 1177-1190
7. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100: 298-304
8. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P (2011) Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 365: 1375-1383
9. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805
10. Horii T, Koike T, Abe Y, Kikuchi R, Unakami H, Iijima K, Imatani A, Ohara S, Shimosegawa T (2011) Two distinct types of cancer of different origin may be mixed in gastroesophageal junction adenocarcinomas in Japan: evidence from direct evaluation of gastric acid secretion. Scand J Gastroenterol 46: 710-719
11. Kahrilas PJ (2011) The problems with surveillance with Barrett's esophagus. N Engl J Med 365: 1437-1438
12. Khor TS, Alfaro EE, Ooi EM, Li Y, Srivastava A, Fujita H, Park Y, Kumarasinghe MP, Lauwers GY (2012) Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus? Am J Surg Pathol 36: 331-342
13. Marx AH, Zielinski M, Kowitz CM, Dancau AM, Thieltges S, Simon R, Choschzick M, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Brümmendorf TH, Fiedler W, Bokemeyer C, Izbicki JR, Sauter G (2010) Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology 57: 418-426
14. Pohl H, Welch G (2005) The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97: 142-146
15. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25: 637-650
16. Siewert JR, Stein HJ, Lordick F (2006) Ösophaguskarzinom. In Siewert JR, Rothmund M, Schumpelick V (eds) Praxis der viszeralchirurgie. Springer, Heidelberg
17. Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Rüschoff J, Schmitt M, Arbogast S, Cappuzzo F (2009) EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 62: 970-977
18. Wijetunge S, Ma Y, DeMeester S, Hagen J, DeMeester T, Chandrasoma P (2010) Association of adenocarcinomas of the distal esophagus, "gastroesophageal junction," and "gastric cardia" with gastric pathology. Am J Surg Pathol 34: 1521-1527
19. Wittekind C, Meyer H-J (2010) TNM Klassifikation maligner Tumoren 7. Auflage. Wiley-VHC, Weinheim
20. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA (2012) Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 18: 546-554